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Background: Beta blockers (BB) are a proven treatment for heart failure with reduced ejection fraction (HFREF), but data regarding their efficacy 
in HF with preserved ejection fraction (HFPEF) is inconclusive.
Methods: We performed a retrospective study of insured patients who received care from a large health system who were hospitalized for HF 
between 1/2000 and 6/2008, and had EF documented. BB exposure was estimated over six-month rolling windows using pharmacy claims data. 
Patients were divided into those with EF<50% (HFREF) and those with EF≥50% (HFPEF). Proportional hazards regression was used to test the 
association between BB exposure and all-cause hospitalization or death with adjustment for baseline covariates and other HF medication exposure. 
We performed analyses stratified by ejection fraction (EF, <50% vs. ≥50%), and overall with a BB exposure*EF interaction term.
Results: A total of 1835 patients met inclusion criteria, of which 741 (40%) had HFPEF. Median follow up was 2.1 years. In adjusted models BB 
exposure was associated with lower risk of death or hospitalization in both patients with HFREF (HR 0.53, p<0.001) and those with HFPEF (HR 0.64 
p<0.002). Formal testing of BB exposure interaction with EF classification showed no difference (p=0.46, beta coefficient=0.13). Further adjusting 
for possible race*BB interactions or BB agent subtype did not alter these findings.
Conclusions: In this large cohort, BB exposure was associated with a similar protective effect in terms of time to death or hospitalization, among 
patients with HFPEF, as compared to HF patients with low EF. These results support the need for an adequately powered randomized clinical trial of 
BB in HFPEF.
